Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration.

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-07-01 Epub Date: 2024-05-29 DOI:10.1080/13543784.2024.2360191

Shogo Hashimoto, Narihito Nagoshi, Masaya Nakamura, Hideyuki Okano

{"title":"Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration.","authors":"Shogo Hashimoto, Narihito Nagoshi, Masaya Nakamura, Hideyuki Okano","doi":"10.1080/13543784.2024.2360191","DOIUrl":null,"url":null,"abstract":"Introduction: Spinal cord injury (SCI) is a condition in which the spinal cord parenchyma is damaged by various factors. The mammalian central nervous system has been considered unable to regenerate once damaged, but recent progress in basic research has gradually revealed that injured neural cells can indeed regenerate. Drug therapy using novel agents is being actively investigated as a new treatment for SCI. One notable treatment method is regeneration therapy using hepatocyte growth factors (HGF).Area covered: HGF has pluripotent neuroregenerative actions, as indicated by its neuroprotective and regenerative effects on the microenvironment and damaged cells, respectively. This review examines these effects in various phases of SCI, from basic research to clinical studies, and the application of this treatment to other diseases.Expert opinion: In regenerative medicine for SCI, drug therapies have tended to be more likely to be developed compared to cell replacement treatment. Nevertheless, there are still challenges to be addressed for these clinical applications due to a wide variety of pathology and animal experimental models of basic study, but HGF could be an effective treatment for SCI with expanded application.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"713-720"},"PeriodicalIF":4.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2024.2360191","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Spinal cord injury (SCI) is a condition in which the spinal cord parenchyma is damaged by various factors. The mammalian central nervous system has been considered unable to regenerate once damaged, but recent progress in basic research has gradually revealed that injured neural cells can indeed regenerate. Drug therapy using novel agents is being actively investigated as a new treatment for SCI. One notable treatment method is regeneration therapy using hepatocyte growth factors (HGF).

Area covered: HGF has pluripotent neuroregenerative actions, as indicated by its neuroprotective and regenerative effects on the microenvironment and damaged cells, respectively. This review examines these effects in various phases of SCI, from basic research to clinical studies, and the application of this treatment to other diseases.

Expert opinion: In regenerative medicine for SCI, drug therapies have tended to be more likely to be developed compared to cell replacement treatment. Nevertheless, there are still challenges to be addressed for these clinical applications due to a wide variety of pathology and animal experimental models of basic study, but HGF could be an effective treatment for SCI with expanded application.

查看原文本刊更多论文

肝细胞生长因子在脊髓损伤再生中的临床应用和潜在多能效应。

导言：脊髓损伤（SCI）是指脊髓实质受到各种因素的损伤。人们一直认为哺乳动物的中枢神经系统一旦受损就无法再生，但最近的基础研究进展逐渐发现，受伤的神经细胞确实可以再生。目前正在积极研究使用新型药物治疗 SCI 的新方法。一种值得注意的治疗方法是使用肝细胞生长因子（HGF）进行再生治疗：肝细胞生长因子具有多能神经再生作用，它对微环境和受损细胞分别具有神经保护和再生作用。本综述探讨了这些作用在 SCI 不同阶段的应用，包括从基础研究到临床研究，以及这种疗法在其他疾病中的应用：在治疗 SCI 的再生医学中，药物疗法往往比细胞替代疗法更有可能得到发展。然而，由于病理和基础研究的动物实验模型种类繁多，这些临床应用仍面临挑战，但随着应用范围的扩大，HGF 可能成为治疗 SCI 的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.